Login   |  Users Online: 616 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
Search Article 
  
Advanced search 
   Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts
RESEARCH ARTICLE
Year : 2009  |  Volume : 30  |  Issue : 1  |  Page : 42-46

A study on Shvasahara Karma of Tamalaki (Phyllanthus fraternus Webster)


1 Ph.D. Scholar, Department of Dravyaguna, Institute of Medical Sciences, Banaras Hindu University, Varanasi- 5 (U. P.), India
2 Professor, Department of Dravyaguna, Institute of Medical Sciences, Banaras Hindu University, Varanasi- 5 (U. P.), India
3 Professor, Department of Medicinal Chemistry, Institute of Medical Sciences, Banaras Hindu University, Varanasi- 5 (U. P.), India
4 Professor, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi- 5 (U. P.), India

Correspondence Address:
Binay Sen
Ph.D. Scholar, Department of Dravyaguna, Institute of Medical Sciences, Banaras Hindu University, Varanasi- 5 (U. P.)
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Tamakashvasa as described in Ayurveda is a disease of Pranavaha Srotas (Respiratory system) involving multiple etiopathogenesis. The clinical features are nearly similar to that of Bronchial asthma described in Modern medicine. This study was designed to explore the therapeutic effect and synergistic action (if any) of a plant Tamalaki (Phyllanthus fraternus Webster). Tsmalaki is included in Shvasahara and Kasahara groups, used in many formulations prescribed in Shvasaroga in Ayurveda. Research works suggest its antihistaminic property in experimental model and effective in non bacterial upper respiratory disorders. The present study comprises 3 groups (each 10 patients). Group A was treated with trial drug Ghanasattva of P. fraternus Webster, 500mg, thrice daily, orally; while Group B was treated with modern standard drugs (a) Tab. Theo-asthalin, thrice daily, orally and (b) Asthalin inhaler, SOS and Group C as combination of both therapies. Total duration of treatment was 45 days. The observations reveal that, Group A has much better improvement in increasing Jaranashakti (t=7.57; p<0.001) and Ruchi (t=9.86; p<0.001) in comparison to Group B and Group C. Moreover, Group C was found more effective in reducing majority of sign-symptoms as such Breathlessness (t=9.00; p<0.001), Cough (t=6.47; p<0.001), Expectoration (t=9.00; p<0.001) Wheezing (t=7.96; p<0.001), Rhonchi (t=7.96; p<0.001), Jaranashakti (t=4.71; p<0.01) and Ruchi (t=6.68; p<0.001).


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1407    
    Printed68    
    Emailed0    
    PDF Downloaded322    
    Comments [Add]    

Recommend this journal